RxDoctor Payments Data

Laura Lynam, MD

Clinical Neurophysiology · Tacoma, WANPI 1295796647

Payments from drug & device makers

$881in general payments, 2019–2025

Across 43 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$176
  • UCB, Inc.$144
  • Sunovion Pharmaceuticals Inc.$140
  • Greenwich Biosciences, Inc.$139
  • Amgen$56
  • Supernus Pharmaceuticals, Inc.$55
  • plus $171 from 7 others

What the payments were for

  • Food & beverage$881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few clinical neurophysiology providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$35,215
Medicare patients
213
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LamictalLamotrigine64$105,453
KeppraLevetiracetam44$100,893
ZonegranZonisamide23$93,458
Lamictal XrLamotrigine20$51,488
TopamaxTopiramate20$48,952
EpidiolexCannabidiol (Cbd)11$45,088
Rufinamide32$40,433
BriviactBrivaracetam25$38,259
AptiomEslicarbazepine Acetate20$34,831
Lacosamide207$21,451
Tegretol XrCarbamazepine19$16,178
Levetiracetam370$15,186
NayzilamMidazolam15$14,493
TrileptalOxcarbazepine21$13,802
Clobazam170$12,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$144$52,75240 claims
Sunovion Pharmaceuticals Inc.Aptiom$140$34,83120 claims
Upsher-smith Laboratories LLCTopiramate$53$9,770131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Tacoma

Where these figures come from

Is this you, or does something look wrong? →